Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms
© 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved..
Mutant calreticulin (CALR) proteins resulting from a -1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact with and activate the thrombopoietin receptor (TpoR/MPL) in the same cell. We report that mutant CALR proteins are secreted and can be found in patient plasma at levels up to 160 ng/mL, with a mean of 25.64 ng/mL. Plasma mutant CALR is found in complex with soluble transferrin receptor 1 (sTFR1) that acts as a carrier protein and increases mutant CALR half-life. Recombinant mutant CALR proteins bound and activated the TpoR in cell lines and primary megakaryocytic progenitors from patients with mutated CALR in which they drive thrombopoietin-independent colony formation. Importantly, the CALR-sTFR1 complex remains functional for TpoR activation. By bioluminescence resonance energy transfer assay, we show that mutant CALR proteins produced in 1 cell can specifically interact in trans with the TpoR on a target cell. In comparison with cells that only carry TpoR, cells that carry both TpoR and mutant CALR are hypersensitive to exogenous mutant CALR proteins and respond to levels of mutant CALR proteins similar to those in patient plasma. This is consistent with CALR-mutated cells that expose TpoR carrying immature N-linked sugars at the cell surface. Thus, secreted mutant CALR proteins will act more specifically on the MPN clone. In conclusion, a chaperone, CALR, can turn into a rogue cytokine through somatic mutation of its encoding gene.
| Errataetall: |
CommentIn: Blood. 2023 Feb 23;141(8):818-820. - PMID 36821187 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:141 |
|---|---|
| Enthalten in: |
Blood - 141(2023), 8 vom: 23. Feb., Seite 917-929 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Calreticulin |
|---|
| Anmerkungen: |
Date Completed 27.02.2023 Date Revised 19.11.2023 published: Print CommentIn: Blood. 2023 Feb 23;141(8):818-820. - PMID 36821187 Citation Status MEDLINE |
|---|
| doi: |
10.1182/blood.2022016846 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM348698933 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM348698933 | ||
| 003 | DE-627 | ||
| 005 | 20231226040855.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1182/blood.2022016846 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1162.xml |
| 035 | |a (DE-627)NLM348698933 | ||
| 035 | |a (NLM)36356299 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Pecquet, Christian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Secreted mutant calreticulins as rogue cytokines in myeloproliferative neoplasms |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.02.2023 | ||
| 500 | |a Date Revised 19.11.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a CommentIn: Blood. 2023 Feb 23;141(8):818-820. - PMID 36821187 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. | ||
| 520 | |a Mutant calreticulin (CALR) proteins resulting from a -1/+2 frameshifting mutation of the CALR exon 9 carry a novel C-terminal amino acid sequence and drive the development of myeloproliferative neoplasms (MPNs). Mutant CALRs were shown to interact with and activate the thrombopoietin receptor (TpoR/MPL) in the same cell. We report that mutant CALR proteins are secreted and can be found in patient plasma at levels up to 160 ng/mL, with a mean of 25.64 ng/mL. Plasma mutant CALR is found in complex with soluble transferrin receptor 1 (sTFR1) that acts as a carrier protein and increases mutant CALR half-life. Recombinant mutant CALR proteins bound and activated the TpoR in cell lines and primary megakaryocytic progenitors from patients with mutated CALR in which they drive thrombopoietin-independent colony formation. Importantly, the CALR-sTFR1 complex remains functional for TpoR activation. By bioluminescence resonance energy transfer assay, we show that mutant CALR proteins produced in 1 cell can specifically interact in trans with the TpoR on a target cell. In comparison with cells that only carry TpoR, cells that carry both TpoR and mutant CALR are hypersensitive to exogenous mutant CALR proteins and respond to levels of mutant CALR proteins similar to those in patient plasma. This is consistent with CALR-mutated cells that expose TpoR carrying immature N-linked sugars at the cell surface. Thus, secreted mutant CALR proteins will act more specifically on the MPN clone. In conclusion, a chaperone, CALR, can turn into a rogue cytokine through somatic mutation of its encoding gene | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Cytokines |2 NLM | |
| 650 | 7 | |a Calreticulin |2 NLM | |
| 650 | 7 | |a Immunologic Factors |2 NLM | |
| 650 | 7 | |a Janus Kinase 2 |2 NLM | |
| 650 | 7 | |a EC 2.7.10.2 |2 NLM | |
| 700 | 1 | |a Papadopoulos, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Balligand, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Chachoua, Ilyas |e verfasserin |4 aut | |
| 700 | 1 | |a Tisserand, Amandine |e verfasserin |4 aut | |
| 700 | 1 | |a Vertenoeil, Gaëlle |e verfasserin |4 aut | |
| 700 | 1 | |a Nédélec, Audrey |e verfasserin |4 aut | |
| 700 | 1 | |a Vertommen, Didier |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Marty, Caroline |e verfasserin |4 aut | |
| 700 | 1 | |a Nivarthi, Harini |e verfasserin |4 aut | |
| 700 | 1 | |a Defour, Jean-Philippe |e verfasserin |4 aut | |
| 700 | 1 | |a El-Khoury, Mira |e verfasserin |4 aut | |
| 700 | 1 | |a Hug, Eva |e verfasserin |4 aut | |
| 700 | 1 | |a Majoros, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Erica |e verfasserin |4 aut | |
| 700 | 1 | |a Zagrijtschuk, Oleh |e verfasserin |4 aut | |
| 700 | 1 | |a Fertig, Tudor E |e verfasserin |4 aut | |
| 700 | 1 | |a Marta, Daciana S |e verfasserin |4 aut | |
| 700 | 1 | |a Gisslinger, Heinz |e verfasserin |4 aut | |
| 700 | 1 | |a Gisslinger, Bettina |e verfasserin |4 aut | |
| 700 | 1 | |a Schalling, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Casetti, Ilaria |e verfasserin |4 aut | |
| 700 | 1 | |a Rumi, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Pietra, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Cavalloni, Chiara |e verfasserin |4 aut | |
| 700 | 1 | |a Arcaini, Luca |e verfasserin |4 aut | |
| 700 | 1 | |a Cazzola, Mario |e verfasserin |4 aut | |
| 700 | 1 | |a Komatsu, Norio |e verfasserin |4 aut | |
| 700 | 1 | |a Kihara, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Sunami, Yoshitaka |e verfasserin |4 aut | |
| 700 | 1 | |a Edahiro, Yoko |e verfasserin |4 aut | |
| 700 | 1 | |a Araki, Marito |e verfasserin |4 aut | |
| 700 | 1 | |a Lesyk, Roman |e verfasserin |4 aut | |
| 700 | 1 | |a Buxhofer-Ausch, Veronika |e verfasserin |4 aut | |
| 700 | 1 | |a Heibl, Sonja |e verfasserin |4 aut | |
| 700 | 1 | |a Pasquier, Florence |e verfasserin |4 aut | |
| 700 | 1 | |a Havelange, Violaine |e verfasserin |4 aut | |
| 700 | 1 | |a Plo, Isabelle |e verfasserin |4 aut | |
| 700 | 1 | |a Vainchenker, William |e verfasserin |4 aut | |
| 700 | 1 | |a Kralovics, Robert |e verfasserin |4 aut | |
| 700 | 1 | |a Constantinescu, Stefan N |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood |d 1946 |g 141(2023), 8 vom: 23. Feb., Seite 917-929 |w (DE-627)NLM000014761 |x 1528-0020 |7 nnns |
| 773 | 1 | 8 | |g volume:141 |g year:2023 |g number:8 |g day:23 |g month:02 |g pages:917-929 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1182/blood.2022016846 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 141 |j 2023 |e 8 |b 23 |c 02 |h 917-929 | ||